Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2023-10-24 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
2023年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2023年第三季度报告" which translates to "2023 Third Quarter Report". It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial changes for the third quarter of 2023. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. It also mentions that the report is unaudited, which is common for interim/quarterly reports. The length of the document (over 13,000 characters) and the presence of substantive financial data confirm it is the actual report, not just an announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2023
2023-10-24 Chinese
关于召开2023年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2023 third extraordinary general meeting (临时股东大会) of the company 拓新药业集团股份有限公司. It includes information about the meeting date, time, location, voting procedures (both onsite and online), registration details, agenda items, and proxy authorization forms. There is no financial data or results reported, nor is it a transcript or presentation. It is not an announcement of voting results but a notice to shareholders about the meeting and how to participate and vote. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings.
2023-10-24 Chinese
关于部分募集资金投资项目结项并将节余募集资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the completion of certain fundraising investment projects and the permanent allocation of surplus raised funds to supplement working capital. It details the use of funds raised from an IPO, the status of investment projects, surplus funds, and approvals from the board, supervisory committee, independent directors, and the sponsoring institution. The document references regulatory compliance with Shenzhen Stock Exchange rules and includes resolutions and opinions from company governance bodies. It is not a full financial report, earnings release, or management discussion, but rather a formal announcement about the use of capital raised and changes in capital allocation. This fits the definition of a Capital/Financing Update (CAP) as it updates on company fundraising and capital structure changes, specifically the reallocation of surplus funds from investment projects to working capital. The document length (5158 characters) and detailed content confirm it is not a mere report publication announcement or a regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2023-10-24 Chinese
中天国富证券有限公司关于拓新药业集团股份有限公司部分募集资金投资项目结项并将节余募集资金永久补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the completion of certain fundraising investment projects by a listed company and the permanent supplementary use of surplus raised funds as working capital. It references regulatory rules related to fundraising management and the Shenzhen Stock Exchange listing rules. The document includes detailed financial figures about the fundraising, project investment, surplus funds, and approvals by the board, supervisory committee, and independent directors. It is not a full annual or interim report, nor an earnings release or call transcript. It is not a simple announcement or certification but a formal verification opinion on the use of raised funds, which aligns with the category of Audit Report / Information (AR) as it involves audit verification and compliance with regulatory fundraising requirements. The document length (4863 characters) and content indicate it is a substantive report rather than a brief announcement or certification. Therefore, the best fitting classification is AR (Audit Report / Information). FY 2023
2023-10-24 Chinese
独立董事关于第四届董事会第二十五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of a company regarding specific agenda items discussed at the 25th meeting of the 4th board of directors. It includes opinions on the use of idle raised funds for cash management, the completion of certain fundraising projects and the permanent replenishment of working capital, and the reappointment of the auditing firm for 2023. The document references compliance with stock exchange rules and company bylaws, and it is clearly related to board meeting matters and approvals. It does not contain financial statements or detailed financial results, nor is it a report or announcement of voting results. It is a governance-related document expressing independent directors' opinions on board matters, which fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2023-10-24 Chinese
第四届监事会第十八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of the company regarding the 18th meeting of the 4th Supervisory Board. It includes approvals of various proposals such as the 2023 Q3 report, use of idle raised funds, project completion, and reappointment of the audit firm. The document does not contain the actual quarterly report or financial statements but refers to the 2023 Q3 report being disclosed elsewhere. The document is relatively short (1697 characters) and serves as an official meeting resolution announcement rather than a full financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution disclosure.
2023-10-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.